REVIEW: REMDESIVIR AS A CANDIDATE FOR COVID-19 TREATMENTJournal: International Journal of Pharmaceutical Sciences and Medicine (IJPSM) (Vol.6, No. 8)
Publication Date: 2021-08-30
Authors : Iffah Anasia; Zulharmita; Ridho Asra;
Page : 161-172
Keywords : Remdesivir; COVID-19; SARS-CoV-2; Ebola virus;
Remdesivir is the first drug that has been approved by the US Food and Drug Administration (FDA) for clinical use in hospitalized patients with COVID-19 disease. From several therapeutic options, Remdesivir is a direct-acting antiviral drug that has previously been tested against the Ebola virus, known to be effective and safe enough to inhibit the replication of SARS-CoV-2. Corona virus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that attacks the respiratory system in humans, this virus can cause mild disorders of the respiratory system, severe lung infections, and even death. Remdesivir is a broad-spectrum antiviral agent that has previously shown antiviral activity against filoviruses (Ebola and Marburg viruses), coronaviruses (SARS-CoV, MERS-CoV, SARS CoV-2), paramyxoviruses (type III influenza virus, Nipah virus, Hendra virus, measles, and mumps virus) and Pnemoviriidae (respiratory syncytial virus).
Other Latest Articles
Last modified: 2021-09-05 02:29:01